↓
 

Drug Pipeline and Conference Coverage

Hepatitis C Drug Pipeline

Drug Pipeline and Conference Coverage
  • Home
  • Clinical Trials Site
  • Commonly Used Terms
  • Category Tree
  • Drug Pipeline
  • HepC Medications Blog

Category Archives: Resistant-associated substitutions (RASs)

Abstract # THU-248 No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies—C. Sarrazin et al.

Drug Pipeline and Conference Coverage

Source:  Abstract # THU-248 No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies—C. Sarrazin et al.

Study Aims and Results: The study was a combination of two studies (POLARIS-1 & 4) looking at treating HCV genotype 1 through 6 (pan-genotypic) direct-acting treatment experienced patients with a combination of sofosbuvir, velpatasvir and voxilaprevir.

A total of 445 patients were treated for 12 weeks with the 3-drug combination.  Thirty-one percent did not have resistant-associated substitutions (RASs) and the remainder had either one RASs or multiple RASs.

Conclusions: The overall cure rates were 97 to 100% regardless of genotype, cirrhosis/no cirrhosis, type of prior treatment failure or RASs. The 12-week treatment of this combination yields very high cure rates for people who have been previously treated with a direct-acting antiviral medication and who have single or single or double RASs.

Editorial Comments: This is good news for patients and medical providers. The triple combination of sofosbuvir, velpatasvir and voxilaprevir in a once-a-day dose is scheduled to be approved by the Food and Drug Administration (FDA) later this year.  It will be a welcome addition to the growing list of HCV medical therapies that are pushing towards 100% cure rates even in people who have not achieved a cure with a prior course of HCV therapy and who have single and double RASs.

To read the June HCV Advocate newsletter, click here

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
Facebooktwitter

Search this site . . .

Last Updated

This Reference Guide was last updated on 4/20/2018

Select a Category

Share This Site

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow HCV Advocate

Facebooktwitter
© 2016 HCVAdvocate.org
↑